2 months ago
India needs to expand biofuel production and consumption to boost its energy security as crude oil prices soar amid the Middle East crisis, according to Tarun Kapoor, an adviser in India's Prime Minister's Office.
"The future of biofuels is about maximizing value from every available resource," Kapoor said at the India Sugar and Bio-Energy Conference.
"From ethanol and compressed biogas to new applications in transport, industry and energy, we must expand the market and fully utilize the capacity we have created," the PM office's adviser said.
India, the world's third-largest crude oil importer, which depended on the Middle East for nearly half of its crude oil imports before the war, has been paying a high price for alternative crude supplies since the Iran war began.
India launched in June a new fuel blend with an 85% ethanol component as part of the fuel flex mobility program to reduce dependence on imported oil.
#kapoor
"The future of biofuels is about maximizing value from every available resource," Kapoor said at the India Sugar and Bio-Energy Conference.
"From ethanol and compressed biogas to new applications in transport, industry and energy, we must expand the market and fully utilize the capacity we have created," the PM office's adviser said.
India, the world's third-largest crude oil importer, which depended on the Middle East for nearly half of its crude oil imports before the war, has been paying a high price for alternative crude supplies since the Iran war began.
India launched in June a new fuel blend with an 85% ethanol component as part of the fuel flex mobility program to reduce dependence on imported oil.
#kapoor
3 months ago
Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright ******* yst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and ******* igned a target price of $95. The stock's potential has been noticed by market participants, as evident from the 46% rise in the last 12 months. With earnings growth expected to continue, HALO is one of our most undervalued growth stocks to buy for the next 10 years.
On a more positive front, on June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, when used with its cancer drug Talvey, significantly improved survival outcomes in a late-stage trial for patients with multiple myeloma. The combination reduced the risk of death by up to 53% compared with the standard treatment. Darzalex Faspro is a front-line multiple myeloma therapy. The combination of two drugs, after about two years of follow-up, reduced the risk of cancer worsening or death by up to 72%. Additionally, at 24 months, about 89% of patients were alive, compared with 79% of those receiving standard care. The positive trial results could benefit HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based on the patented recombinant human hyaluronidase enzyme that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. The company was founded in 1998 and is headquartered in San Diego, California.
While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best AI Stocks to Watch in July and 12 Best Dow Stocks to Invest In Right Now.
On a more positive front, on June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, when used with its cancer drug Talvey, significantly improved survival outcomes in a late-stage trial for patients with multiple myeloma. The combination reduced the risk of death by up to 53% compared with the standard treatment. Darzalex Faspro is a front-line multiple myeloma therapy. The combination of two drugs, after about two years of follow-up, reduced the risk of cancer worsening or death by up to 72%. Additionally, at 24 months, about 89% of patients were alive, compared with 79% of those receiving standard care. The positive trial results could benefit HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based on the patented recombinant human hyaluronidase enzyme that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. The company was founded in 1998 and is headquartered in San Diego, California.
While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best AI Stocks to Watch in July and 12 Best Dow Stocks to Invest In Right Now.
4 months ago
When the CEO of Morningstar sat down to speak with the president of the largest alternative ******* et management firm, he asked a question that is likely on many financial advisors' minds.
While the head of the investment research, technology and portfolio management firm, Kunal Kapoor, acknowledged in his keynote interview with Jon Gray of Blackstone at Morningstar's conference last month in Chicago that Gray's firm "has not had trouble raising capital," he pointed out that there has been "a noticeable slowdown in institutional fundraising."
"So if you're an advisor sitting here and you're looking at this slowdown in fundraising," Kapoor said, "it feels like a natural question to be asking, 'Why is private equity slash private credit actually coming to us now when they're struggling elsewhere to raise capital?'"
Despite the headlines around fundraising and redemption withdrawals across private investments in general over the past year, Blackstone raised about $70 billion in the first quarter, with half from institutional clients, Gray noted. But the firm has also been "been focused on individual investors and their advisors for 25 years," and Gray's team continues to believe that retail clients are "underserved" when it comes to private investments, he said.
"We feel incredibly proud of what we've been able to do in the private ******* e for our investors," Gray said. "So I think, for advisors, the question is, 'is this manager committed to the ******* e? Do they have the infrastructure? Do they have the ability in the semiliquid world to deploy the capital? Do they have the commitment to transparency to do evaluations in the right way?' I think manager quality and commitment to this ******* e really matters. If done in the right way, this has been a very helpful part of your portfolio."
While the head of the investment research, technology and portfolio management firm, Kunal Kapoor, acknowledged in his keynote interview with Jon Gray of Blackstone at Morningstar's conference last month in Chicago that Gray's firm "has not had trouble raising capital," he pointed out that there has been "a noticeable slowdown in institutional fundraising."
"So if you're an advisor sitting here and you're looking at this slowdown in fundraising," Kapoor said, "it feels like a natural question to be asking, 'Why is private equity slash private credit actually coming to us now when they're struggling elsewhere to raise capital?'"
Despite the headlines around fundraising and redemption withdrawals across private investments in general over the past year, Blackstone raised about $70 billion in the first quarter, with half from institutional clients, Gray noted. But the firm has also been "been focused on individual investors and their advisors for 25 years," and Gray's team continues to believe that retail clients are "underserved" when it comes to private investments, he said.
"We feel incredibly proud of what we've been able to do in the private ******* e for our investors," Gray said. "So I think, for advisors, the question is, 'is this manager committed to the ******* e? Do they have the infrastructure? Do they have the ability in the semiliquid world to deploy the capital? Do they have the commitment to transparency to do evaluations in the right way?' I think manager quality and commitment to this ******* e really matters. If done in the right way, this has been a very helpful part of your portfolio."
1 yr. ago
ARKS, the premium lifestyle brand founded by actor Ranbir Kapoor, has entered a new realm of self-expression with the launch of its debut fragrance, ARKS Day. Known for its...
Read more: https://indianretailer.com...
#D2C #business #news #market #updates #newlaunche #perfumes #ARKS
https://indianretailer.com...
Read more: https://indianretailer.com...
#D2C #business #news #market #updates #newlaunche #perfumes #ARKS
https://indianretailer.com...
1 yr. ago
Mira Rajput Kapoor reveals she refused to invest in a restaurant as it doesn’t align with her principles; says, “I am a vegetarian and I am not going to be involved in a business…” : Bollywood News
